Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 361

1.

Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast.

Natsis NE, Merola JF, Weinberg JM, Wu JJ, Orbai AM, Bagel J, Gottlieb AB.

Am J Clin Dermatol. 2019 Aug 26. doi: 10.1007/s40257-019-00468-0. [Epub ahead of print]

PMID:
31452091
2.

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase 2 Trial.

Helliwell PS, Deodhar A, Gottlieb AB, Boehncke WH, Xu XL, Xu S, Wang Y, Hsia EC, Gladman DD, Ritchlin CT.

Arthritis Care Res (Hoboken). 2019 Aug 17. doi: 10.1002/acr.24046. [Epub ahead of print]

PMID:
31421033
3.

Clinical considerations for the management of psoriasis in women.

Gottlieb AB, Ryan C, Murase JE.

Int J Womens Dermatol. 2019 Apr 10;5(3):141-150. doi: 10.1016/j.ijwd.2019.04.021. eCollection 2019 Jul. Review.

4.

Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.

Elmets CA, Lim HW, Stoff B, Connor C, Cordoro KM, Lebwohl M, Armstrong AW, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Leonardi CL, Lichten J, Mehta NN, Paller AS, Parra SL, Pathy AL, Farley Prater EA, Rupani RN, Siegel M, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A.

J Am Acad Dermatol. 2019 Sep;81(3):775-804. doi: 10.1016/j.jaad.2019.04.042. Epub 2019 Jul 25.

PMID:
31351884
5.

Sustained Efficacy of Secukinumab in Subjects with Moderate-to-Severe Palmoplantar Psoriasis: 2·5-Year Results from GESTURE, a Randomized, Double-blind, Placebo-controlled Trial.

Gottlieb AB, Kubanov A, van Doorn M, Sullivan J, Papp KA, You R, Regnault P, Frueh JA.

Br J Dermatol. 2019 Jul 8. doi: 10.1111/bjd.18331. [Epub ahead of print]

PMID:
31286480
6.

Measuring Psoriatic Arthritis Symptoms, A Core Domain in Psoriasis Clinical Trials.

Perez-Chada LM, Gottlieb AB, Cohen J, Mease P, Duffin KC, Garg A, Latella J, Armstrong AW, Ogdie A, Merola JF.

J Am Acad Dermatol. 2019 Jun 1. pii: S0190-9622(19)30879-5. doi: 10.1016/j.jaad.2019.05.075. [Epub ahead of print]

PMID:
31163240
7.

Report of the Skin Research Workgroups from the GRAPPA 2018 Annual Meeting.

Perez-Chada LM, Merola JF, Armstrong AW, Gottlieb AB.

J Rheumatol Suppl. 2019 Jun;95:28-32. doi: 10.3899/jrheum.190124.

PMID:
31154401
8.

Prologue: 2018 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

Callis Duffin K, Gladman DD, Gottlieb AB, Goel N.

J Rheumatol Suppl. 2019 Jun;95:1-3. doi: 10.3899/jrheum.190112.

PMID:
31154397
9.
10.

Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review

Kahn JS, Casseres RG, Her MJ, Dumont N, Gottlieb AB, Rosmarin D.

J Drugs Dermatol. 2019 Apr 1;18(4). pii: S1545961619P0387X.

PMID:
31013012
11.

Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials.

McInnes IB, Puig L, Gottlieb AB, Ritchlin CT, Song M, You Y, Kafka S, Morgan GJ, Rahman P, Kavanaugh A; PSUMMIT 1 and 2 Study Groups.

J Rheumatol. 2019 Apr 1. pii: jrheum.180792. doi: 10.3899/jrheum.180792. [Epub ahead of print]

PMID:
30936281
12.

Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry.

Kavanaugh A, Papp K, Gottlieb AB, de Jong EMGJ, Chakravarty SD, Kafka S, Langholff W, Farahi K, Srivastava B, Scher JU.

BMC Rheumatol. 2018 Sep 29;2:29. doi: 10.1186/s41927-018-0034-7. eCollection 2018.

13.

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, Crowell K, Eisen DB, Gottlieb AB, Hamzavi I, Hazen PG, Jaleel T, Kimball AB, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y.

J Am Acad Dermatol. 2019 Jul;81(1):76-90. doi: 10.1016/j.jaad.2019.02.067. Epub 2019 Mar 11.

PMID:
30872156
14.

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.

Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, Crowell K, Eisen DB, Gottlieb AB, Hamzavi I, Hazen PG, Jaleel T, Kimball AB, Kirby J, Lowes MA, Micheletti R, Miller A, Naik HB, Orgill D, Poulin Y.

J Am Acad Dermatol. 2019 Jul;81(1):91-101. doi: 10.1016/j.jaad.2019.02.068. Epub 2019 Mar 11.

PMID:
30872149
15.

Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.

Prussick L, Rothstein B, Joshipura D, Saraiya A, Turkowski Y, Abdat R, Alomran A, Zancanaro P, Kachuk C, Dumont N, Gottlieb AB, Rosmarin D.

Br J Dermatol. 2019 Sep;181(3):609-611. doi: 10.1111/bjd.17822. Epub 2019 May 12. No abstract available.

PMID:
30801662
16.

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA.

J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13. Review.

PMID:
30772098
17.

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A.

J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058. Epub 2019 Feb 13. Review.

PMID:
30772097
18.

Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.

Thorlacius L, Garg A, Riis PT, Nielsen SM, Bettoli V, Ingram JR, Del Marmol V, Matusiak L, Pascual JC, Revuz J, Sartorius K, Tzellos T, van der Zee HH, Zouboulis CC, Saunte DM, Gottlieb AB, Christensen R, Jemec GBE.

Br J Dermatol. 2019 Sep;181(3):483-491. doi: 10.1111/bjd.17716. Epub 2019 Jun 6.

PMID:
30724351
19.

Improving health literacy and treatment understanding of hidradenitis suppurativa using group educational interventions.

Prussick L, Tonelli S, Gottlieb AB, Joshipura D, Alomran A, Zancanaro P, Courtney Kachuk RN, Dumont N, Rosmarin D.

J Dermatolog Treat. 2019 Nov;30(7):708-713. doi: 10.1080/09546634.2018.1562536. Epub 2019 Jun 24.

PMID:
30582391
20.

Clinical Goals and Barriers to Effective Psoriasis Care.

Strober BE, van der Walt JM, Armstrong AW, Bourcier M, Carvalho AVE, Chouela E, Cohen AD, de la Cruz C, Ellis CN, Finlay AY, Gottlieb AB, Gudjonsson JE, Iversen L, Kleyn CE, Leonardi CL, Lynde CW, Ryan C, Theng CT, Valenzuela F, Vender R, Wu JJ, Young HS, Kimball AB.

Dermatol Ther (Heidelb). 2019 Mar;9(1):5-18. doi: 10.1007/s13555-018-0279-5. Epub 2018 Dec 21.

21.

Bimekizumab for the treatment of psoriatic disease.

Natsis NE, Gottlieb AB.

Expert Opin Biol Ther. 2018 Dec;18(12):1193-1197. doi: 10.1080/14712598.2018.1538351. Epub 2018 Oct 23. Review.

PMID:
30332893
22.

Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.

Coates LC, Gottlieb AB, Merola JF, Boone C, Szumski A, Chhabra A.

J Rheumatol. 2019 Feb;46(2):160-165. doi: 10.3899/jrheum.180249. Epub 2018 Oct 15.

PMID:
30323006
23.
24.

Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.

Blauvelt A, Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, Drew J, Rolleri R, Gottlieb AB.

J Eur Acad Dermatol Venereol. 2019 Mar;33(3):546-552. doi: 10.1111/jdv.15258. Epub 2018 Oct 14.

25.

Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.

Walsh JA, Gottlieb AB, Hoepken B, Nurminen T, Mease PJ.

Clin Rheumatol. 2018 Dec;37(12):3285-3296. doi: 10.1007/s10067-018-4227-7. Epub 2018 Sep 6. Erratum in: Clin Rheumatol. 2018 Oct 11;:.

PMID:
30191421
26.

Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.

Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R.

Br J Dermatol. 2019 Jan;180(1):67-75. doi: 10.1111/bjd.17149. Epub 2018 Oct 10.

PMID:
30188571
27.

Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative.

Perez-Chada LM, Cohen JM, Gottlieb AB, Duffin KC, Garg A, Latella J, Armstrong AW, Ogdie A, Merola JF.

Arch Dermatol Res. 2018 Nov;310(9):701-710. doi: 10.1007/s00403-018-1855-3. Epub 2018 Aug 25.

PMID:
30167814
28.

Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis.

Salame N, Perez-Chada LM, Singh S, Callis Duffin K, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW.

Dermatology. 2018;234(5-6):157-165. doi: 10.1159/000490413. Epub 2018 Aug 17.

29.

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD.

Rheumatology (Oxford). 2018 Oct 1;57(10):1777-1788. doi: 10.1093/rheumatology/key161.

30.

Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies.

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, Gottlieb AB, Gisondi P, Wu JJ, Thyssen JP, Egeberg A.

J Am Acad Dermatol. 2019 Jan;80(1):251-265.e19. doi: 10.1016/j.jaad.2018.06.027. Epub 2018 Jun 19.

PMID:
29928910
31.

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.

Deodhar A, Gottlieb AB, Boehncke WH, Dong B, Wang Y, Zhuang Y, Barchuk W, Xu XL, Hsia EC; CNTO1959PSA2001 Study Group.

Lancet. 2018 Jun 2;391(10136):2213-2224. doi: 10.1016/S0140-6736(18)30952-8. Epub 2018 Jun 1.

PMID:
29893222
32.

Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials.

Callis Duffin K, Merola JF, Christensen R, Latella J, Garg A, Gottlieb AB, Armstrong AW.

JAMA Dermatol. 2018 Oct 1;154(10):1137-1144. doi: 10.1001/jamadermatol.2018.1165.

33.

Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting.

Gottlieb AB, Coates LC, van Mens LJJ, Armstrong AW, Merola JF.

J Rheumatol Suppl. 2018 Jun;94:40-43. doi: 10.3899/jrheum.180137.

PMID:
29858353
34.

Prologue: 2017 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

Helliwell PS, Gladman DD, Gottlieb AB.

J Rheumatol Suppl. 2018 Jun;94:1-3. doi: 10.3899/jrheum.180129.

PMID:
29858345
35.

Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.

Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather JC, Yosipovitch G, Gottlieb AB, Merola JF, Callis Duffin K, Fretzin S, Osuntokun OO, Burge R, Naegeli AN, Yang FE, Lin CY, Todd K, Potts Bleakman A; IXORA-Q Study Group.

Br J Dermatol. 2018 Oct;179(4):844-852. doi: 10.1111/bjd.16736. Epub 2018 Jul 22.

PMID:
29747232
36.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2).

Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, Peterson L, Arendt C, Burge D, Reich K.

J Am Acad Dermatol. 2018 Aug;79(2):302-314.e6. doi: 10.1016/j.jaad.2018.04.012. Epub 2018 Apr 13.

37.

A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process.

Thorlacius L, Ingram JR, Villumsen B, Esmann S, Kirby JS, Gottlieb AB, Merola JF, Dellavalle R, Nielsen SM, Christensen R, Garg A, Jemec GBE; HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC).

Br J Dermatol. 2018 Sep;179(3):642-650. doi: 10.1111/bjd.16672. Epub 2018 Jul 5.

38.

Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.

Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, Cioffi C, Blauvelt A.

J Am Acad Dermatol. 2018 Aug;79(2):277-286.e10. doi: 10.1016/j.jaad.2018.03.037. Epub 2018 Mar 30.

39.

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis.

Gottlieb AB, Papp KA, Birbara CA, Shuler CL, Burge R, Erickson J, Kerr L, Mease PJ.

J Am Acad Dermatol. 2018 Sep;79(3):593-595. doi: 10.1016/j.jaad.2018.03.008. Epub 2018 Mar 17. No abstract available.

PMID:
29559395
40.

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis.

van der Heijde D, Deodhar A, FitzGerald O, Fleischmann R, Gladman D, Gottlieb AB, Hoepken B, Bauer L, Irvin-Sellers O, Khraishi M, Peterson L, Turkiewicz A, Wollenhaupt J, Mease PJ.

RMD Open. 2018 Mar 14;4(1):e000582. doi: 10.1136/rmdopen-2017-000582. eCollection 2018. Erratum in: RMD Open. 2018 Mar 26;4(1):.

41.

Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.

Gottlieb AB, Gordon K, Hsu S, Elewski B, Eichenfield LF, Kircik L, Rastogi S, Pillai R, Israel R.

J Eur Acad Dermatol Venereol. 2018 Aug;32(8):1305-1313. doi: 10.1111/jdv.14913. Epub 2018 Mar 30.

PMID:
29512200
42.

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.

Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ.

Br J Dermatol. 2018 Aug;179(2):320-328. doi: 10.1111/bjd.16464. Epub 2018 May 23.

PMID:
29488226
43.

Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM).

Salame N, Torres J, Sandhu J, Callis Duffin K, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW.

Dermatology. 2018;234(3-4):112-119. doi: 10.1159/000490460. Epub 2018 Jul 18.

PMID:
31112972
44.

The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health.

Gottlieb AB, Kirby B, Ryan C, Naegeli AN, Burge R, Potts Bleakman A, Anatchkova MD, Cather J.

Dermatol Ther (Heidelb). 2018 Mar;8(1):33-44. doi: 10.1007/s13555-017-0212-3. Epub 2017 Dec 4.

45.

The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS).

Gottlieb AB, Kirby B, Ryan C, Naegeli AN, Burge R, Potts Bleakman A, Anatchkova MD, Yosipovitch G.

Dermatol Ther (Heidelb). 2018 Mar;8(1):45-56. doi: 10.1007/s13555-017-0213-2. Epub 2017 Dec 4.

46.

Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA × BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data.

Gottlieb AB, Merola JF, Chen R, Levi E, Duffin KC.

J Am Acad Dermatol. 2017 Dec;77(6):1178-1180. doi: 10.1016/j.jaad.2017.06.162. No abstract available.

47.

Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II.

Thorlacius L, Garg A, Ingram JR, Villumsen B, Theut Riis P, Gottlieb AB, Merola JF, Dellavalle R, Ardon C, Baba R, Bechara FG, Cohen AD, Daham N, Davis M, Emtestam L, Fernández-Peñas P, Filippelli M, Gibbons A, Grant T, Guilbault S, Gulliver S, Harris C, Harvent C, Houston K, Kirby JS, Matusiak L, Mehdizadeh A, Mojica T, Okun M, Orgill D, Pallack L, Parks-Miller A, Prens EP, Randell S, Rogers C, Rosen CF, Choon SE, van der Zee HH, Christensen R, Jemec GBE.

Br J Dermatol. 2018 Mar;178(3):715-721. doi: 10.1111/bjd.16093. Epub 2018 Feb 1.

48.

Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.

Puig L, Augustin M, Blauvelt A, Gottlieb AB, Vender R, Korman NJ, Thaçi D, Zhao Y, Gilloteau I, Sherif B, Williams N, Guana A, Lebwohl MG.

J Am Acad Dermatol. 2018 Apr;78(4):741-748. doi: 10.1016/j.jaad.2017.10.025. Epub 2017 Oct 21.

PMID:
29066271
49.

Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.

Bissonnette R, Kerdel F, Naldi L, Papp K, Galindo C, Langholff W, Tang KL, Szapary P, Fakharzadeh S, Srivastava B, Goyal K, Gottlieb AB.

J Drugs Dermatol. 2017 Oct 1;16(10):1002-1013.

PMID:
29036254
50.

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.

McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, Kajekar R, Delicha EM, Pricop L, Mpofu S.

Rheumatology (Oxford). 2017 Nov 1;56(11):1993-2003. doi: 10.1093/rheumatology/kex301.

Supplemental Content

Loading ...
Support Center